Arina V. Nostaeva

Arina V. Nostaeva

Auto-generated profile, based on publicly available information

Arina V. Nostaeva

St. Petersburg State Budgetary Healthcare Institution

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YTYakov Tsepilov
Yakov Tsepilov
EEElizaveta Evgenevna Elgaeva
Elizaveta Evgenevna Elgaeva
ANArina V. Nostaeva
Arina V. Nostaeva
RCRoger Compte
Roger Compte
IKIvan Kuznetsov
Ivan Kuznetsov
YAYurii S. Aulchenko
Yurii S. Aulchenko
Chronic back pain (CBP) is a complex heritable trait and a major cause of disability worldwide. We developed and validated a genome-wide polygenic risk score (PRS) for CBP using a large-scale GWAS based on UK Biobank participants of European ancestry (N = 265,000). The PRS showed poor overall predictive ability (AUC = 0.56 and OR = 1.24 per SD, 95% CI: 1.22–1.26), but individuals from the 99th percentile of PRS distribution had a nearly two-fold increased risk of CBP (OR = 1.82, 95% CI: 1.60–2.06). We validated the PRS on an independent TwinsUK sample, obtaining a similar magnitude of effect. The PRS was significantly associated with various ICD-10 and OPCS-4 diagnostic codes, including chronic ischemic heart disease (OR = 1.1, p-value = 4.8 × 10−15), obesity, metabolism-related traits, spine disorders, disc degeneration, and arthritis-related disorders. PRS and environment interaction analysis with twelve known CBP risk factors revealed no significant results, suggesting that the magnitude of G × E interactions with studied factors is small. The limited predictive ability of the PRS that we developed is likely explained by the complexity, heterogeneity, and polygenicity of CBP, for which sample sizes of a few hundred thousand are insufficient to estimate small genetic effects robustly.

26 December 2024 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
ANArina Nostaeva
Arina Nostaeva
VSValentin Shimansky
Valentin Shimansky
SASvetlana Apalko
Svetlana Apalko
IKIvan Kuznetsov
Ivan Kuznetsov
NSNatalya Sushentseva
Natalya Sushentseva
SSSergey Shcherbak
Sergey Shcherbak
The course of COVID-19 is highly variable, with genetics playing a significant role. Through large-scale genetic association studies, a link between single nucleotide polymorphisms and disease susceptibility and severity was established. However, individual single nucleotide polymorphisms identified thus far have shown modest effects, indicating a polygenic nature of this trait, and individually have limited predictive performance. To address this limitation, we investigated the performance of a polygenic risk score model in the context of COVID-19 severity in a Russian population. A genome-wide polygenic risk score model including information from over a million common single nucleotide polymorphisms was developed using summary statistics from the COVID-19 Host Genetics Initiative consortium. Low-coverage sequencing (5x) was performed for ~1000 participants, and polygenic risk score values were calculated for each individual. A multivariate logistic regression model was used to analyse the association between polygenic risk score and COVID-19 outcomes. We found that individuals in the top 10% of the polygenic risk score distribution had a markedly elevated risk of severe COVID-19, with adjusted odds ratio of 2.9 (95% confidence interval: 1.8–4.6, p-value = 4e-06), and more than four times higher risk of mortality from COVID-19 (adjusted odds ratio = 4.3, p-value = 2e-05). This study highlights the potential of polygenic risk score as a valuable tool for identifying individuals at increased risk of severe COVID-19 based on their genetic profile.

20 November 2023 in medRxiv
Verified
Preprint
Open access
PDF file
ANArina V. Nostaeva
Arina V. Nostaeva
VSValentin Sergeevich Shimansky
Valentin Sergeevich Shimansky
SAsvetlana apalko
svetlana apalko
IKIvan Kuznetsov
Ivan Kuznetsov
NSNatalya N. Sushentseva
Natalya N. Sushentseva
SSSergey G. Shcherbak
Sergey G. Shcherbak
The course of COVID-19 is characterized by wide variability, with genetics playing a contributing role. Through large-scale genetic association studies, a significant link between genetic variants and disease severity was established. However, individual genetic variants identified thus far have shown modest effects, indicating a polygenic nature of this trait. To address this, a polygenic risk score (PRS) can be employed to aggregate the effects of multiple single nucleotide polymorphisms (SNPs) into a single number, allowing practical application to individuals within a population. In this work, we investigated the performance of a PRS model in the context of COVID-19 severity in 1,085 Russian participants using low-coverage NGS sequencing. By developing a genome-wide PRS model based on summary statistics from the COVID-19 Host Genetics Initiative consortium, we demonstrated that the PRS, which incorporates information from over a million common genetic variants, can effectively identify individuals at significantly higher risk for severe COVID-19. The findings revealed that individuals in the top 10% of the PRS distribution had a markedly elevated risk of severe COVID-19, with an odds ratio (OR) of 2.1 (95% confidence interval (CI): 1.4–3.2, p-value = 0.00046). Furthermore, incorporating the PRS into the prediction model significantly improved its accuracy compared to a model that solely relied on demographic information (p-value < 0.0001). This study highlights the potential of PRS as a valuable tool for identifying individuals at increased risk of severe COVID-19 based on their genetic profile.

1 July 2024 in Genes & Cells
Verified
Journal Article
Open access
PDF file
SAsvetlana apalko
svetlana apalko
ANArina V. Nostaeva
Arina V. Nostaeva
VSValentin Sergeevich Shimansky
Valentin Sergeevich Shimansky
NSNatalya N. Sushentseva
Natalya N. Sushentseva
OPOleg Popov
Oleg Popov
ЩГЩербак Сергей Григорьевич
Щербак Сергей Григорьевич
BACKGROUND: Human genotype is a factor that determines the severity of COVID-19. Previously, a large-scale whole-genome association study of the COVID-19 Host Genetics Initiative (2021) investigated the association of genetic variants at multiple loci with COVID-19 severity. The genetic variants that have the greatest effect on COVID-19 severity are expected to have a low frequency in the population. Therefore, the study of rare variants may provide additional insights into the disease pathogenesis and thus help in the development of prevention and treatment options. AIM: To search for genes enriched for rare genetic variants associated with COVID-19 severity in the Russian population by replication analysis. METHODS: The clinical exome of a Russian cohort of patients was sequenced based on the St. Petersburg State Budgetary Institution “City Hospital No. 40” and St Petersburg University. The study used biomaterial from patients hospitalized at City Hospital No. 40 diagnosed with COVID-19 and healthy individuals (population control group). The severity of the course of COVID-19 was determined according to the results of lung computed tomography. The list of genes for subsequent replication was generated by a literature review. Burden test methods were used for the replication analysis of genes associated with COVID-19 severity. RESULTS: In total, 701 clinical exomes were sequenced from 263 individuals with severe COVID-19 and 438 healthy individuals. In the literature review, 18 genes associated with severe COVID-19 were included in the replication analysis. The replication analysis did not identify any genes whose association with severe COVID-19 was confirmed in the study cohort. CONCLUSION: The replication analysis did not identify any genes that showed a significant association between the functional variant enrichment and COVID-19 severity. However, the direction of the correlation was consistent with the findings of previous studies. Expanding the study cohort would increase the power of the tests and allow us to detect additional rare variants that influence the severity of COVID-19 progression.

15 February 2024 in medRxiv
Verified
Preprint
Open access
PDF file
EEElizaveta Evgenevna Elgaeva
Elizaveta Evgenevna Elgaeva
IZIrina Zorkoltseva
Irina Zorkoltseva
ANArina V. Nostaeva
Arina V. Nostaeva
DVDmitrii A. Verzun
Dmitrii A. Verzun
ETEvgeny S. Tiys
Evgeny S. Tiys
YTYakov Tsepilov
Yakov Tsepilov
Chronic back pain (CBP) is a disabling condition with a lifetime prevalence of 40% and a substantial socioeconomic burden. Because of the high heterogeneity of CBP, subphenotyping may be necessary to improve prediction and support personalized treatment for those with CBP. The lack of distinct cellular and molecular markers for CBP complicates the task of subphenotyping. To investigate CBP subphenotypes, we decomposed the genetic background of CBP into a shared genetic background common to other chronic pain conditions (back, neck, hip, knee, stomach, and head pain) and unshared genetic background related only to CBP. We showed that the shared and unshared genetic backgrounds of CBP differ in their biological functions: the first one is likely to control processes mainly in nervous, immune and musculoskeletal systems underlying chronic pain development regardless its site, while the second may contribute more to local processes in spine leading to chronic pain precisely in the back. We identified 18 genes with shared impact across different chronic pain conditions and two genes that were specific for CBP. These findings may contribute to future development of targets and new biomarkers for chronic pain management. Next, among people with CBP, we demonstrated that polygenic risk scores accounting for the shared and unshared genetic backgrounds of CBP may underpin different subphenotypes of CBP cases. These subphenotypes are characterized by varying genetic predisposition to a wide array of medical conditions and interventions such as diabetes mellitus, myocardial infarction, diagnostic endoscopic procedures, and surgery involving muscles, bones, and joints. The proposed genetic decomposition framework holds promise for investigating the genetic underpinnings of other heterogeneous diseases. Author Summary Chronic back pain (CBP) is a prevalent disabling health problem with heterogeneous clinical presentation and natural history. This may contribute to generic pain treatment approaches not sufficiently effective when prescribed for patients with certain characteristics. Development of more personalized treatment is needed, and may benefit from a deep understanding of CBP biology, such as genomics. It is known that chronic pain is under the control of both environmental and genetic background. Here we applied bioinformatic methods to study the genetic background of CBP decomposed into two parts: a shared one common to six distinct chronic pain types, and unshared, which is specific to CBP. This approach allowed us to identify more genes potentially involved in CBP development. Among them 18 belong to the shared genetic background contributing to development of chronic pain in general, and two are specific for CBP. We demonstrate that these two parts of the genetic background of CBP are associated with distinct biological pathways and underlie predisposition to different medical states and procedures, involving diabetes, myocardial infarction, and musculoskeletal surgery. Decomposition of CBP genetic background into shared and unshared may provide a better understanding of mechanisms of CBP and facilitate development of personalized pain treatment.

10 July 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SSSodbo Sharapov
Sodbo Sharapov
ATAnna Timoshchuk
Anna Timoshchuk
OZOlga Zaytseva
Olga Zaytseva
DMDenis Evgenevich Maslov
Denis Evgenevich Maslov
ASAnna Soplenkova
Anna Soplenkova
YAYurii S. Aulchenko
Yurii S. Aulchenko
More than a half of plasma proteins are N-glycosylated. Most of them are synthesized, glycosylated, and secreted to the bloodstream by liver and lymphoid tissues. While associations with N-glycosylation are implicated in the rising number of liver, cardiometabolic, and immune diseases, little is known about the genetic regulation of this process. Here, we performed the largest genome-wide association study of N-glycosylation of the blood plasma proteome in 10,000 individuals. We doubled the number of genetic loci known to be associated with blood N-glycosylation by identifying 16 novel loci and prioritizing 13 novel genes contributing to N-glycosylation. Among these were the GCKR , TRIB1 , HP, SERPINA1 and CFH genes. These genes are predominantly expressed in the liver and show a previously unknown genetic link between plasma protein N-glycosylation, metabolic and liver diseases, and inflammatory response. By integrating glycomics, proteomics, transcriptomics, and genomics, we provide a resource that facilitates deeper exploration of disease pathogenesis and supports the discovery of glycan-based biomarkers.